Abstract: The invention provides a composition for stimulating an immune response in a patient having an adenocarcinoma, including a patient having colorectal cancer, containing allogeneic tumor cells and a physiologically acceptable carrier. The allogeneic tumor cells can be SW620, COLO 205, or SW403 cells. The invention composition can also contain an allogeneic cell expressing a cytokine. An allogeneic tumor cell can additionally express CD80. The invention additionally provides a method of stimulating an immune response in a patient having an adenocarcinoma, including a patient having colorectal cancer, by administering to the patient one or more allogeneic tumor cells, wherein the allogeneic cell stimulates an immune response to autologous tumor cells in the patient.

Abstract: Novel methods for reducing the heterogeneity of secreted monoclonal antibodies are disclosed. The first method comprises incubating the heterogeneous antibodies at low pH for a length of time sufficient to convert the heterogeneous forms of antibodies into substantially homogeneous forms. Another method produces the same result using ascites fluid, while yet another method produces the same result using carboxypeptidase. The homogeneous antibodies can then be purified in high yield.

Abstract: A composition comprising a non-covalent immunocomplex of an anthracycline agent and an antibody selected to bind a target antigen and enhance the cytotoxicity of the anthracycline agent is disclosed. In accordance with the invention, the efficacy of an anthracycline as an anti-tumor agent for use in in vivo therapy is enhanced by administering to a patient a non-covalent immunocomplex provided herein.